Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Common Equity: 2018-2025

Historic Common Equity for Whitehawk Therapeutics (WHWK) over the last 8 years, with Sep 2025 value amounting to $157.2 million.

  • Whitehawk Therapeutics' Common Equity rose 128.22% to $157.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.2 million, marking a year-over-year increase of 128.22%. This contributed to the annual value of $52.5 million for FY2024, which is 50.11% down from last year.
  • Latest data reveals that Whitehawk Therapeutics reported Common Equity of $157.2 million as of Q3 2025, which was down 8.66% from $172.1 million recorded in Q2 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Common Equity peaked at $221.7 million during Q1 2025, and registered a low of $35.2 million during Q2 2021.
  • Moreover, its 3-year median value for Common Equity was $118.2 million (2023), whereas its average is $122.0 million.
  • As far as peak fluctuations go, Whitehawk Therapeutics' Common Equity skyrocketed by 1,197.22% in 2021, and later plummeted by 50.11% in 2024.
  • Over the past 5 years, Whitehawk Therapeutics' Common Equity (Quarterly) stood at $136.4 million in 2021, then grew by 16.11% to $158.4 million in 2022, then crashed by 33.58% to $105.2 million in 2023, then tumbled by 50.11% to $52.5 million in 2024, then soared by 128.22% to $157.2 million in 2025.
  • Its last three reported values are $157.2 million in Q3 2025, $172.1 million for Q2 2025, and $221.7 million during Q1 2025.